irinotecan hydrochloride trihydrate
PolandDrugs containing this active substance
-
The medicine is used in adults for the treatment of advanced colorectal cancer. It may be administered alone or in combination with other medicines.
Form: solution for infusion, concentrate
Active substance Dosage irinotecan hydrochloride trihydrate 20 mg/ml ATC: L01XX19
Manufacturer: Accord Healthcare Polska Sp. z o.o.
-
The medicinal product is used to treat patients with advanced colorectal cancer (colon and rectum) or metastatic colorectal cancer. It may be administered as monotherapy in patients whose disease has recurred or progressed after previous treatment with 5-fluorouracil.
Form: solution for infusion, concentrate
Active substance Dosage irinotecan hydrochloride trihydrate 20 mg/ml ATC: L01CE02
-
The medicine is used to treat patients with advanced colorectal cancer (including metastatic cancer). It may also be administered alone if patients with metastatic colorectal cancer experience a recurrence or worsening of the disease after previous treatment with fluorouracil.
Form: solution for infusion, concentrate
Active substance Dosage irinotecan hydrochloride trihydrate 20 mg/ml ATC: L01CE02
Manufacturer: Fresenius Kabi Deutschland GmbH
-
This is an anticancer medication used in the treatment of patients with advanced or metastatic colorectal or rectal cancer. It may be administered in combination with other drugs or alone if the disease has recurred after previous therapy with fluorouracil.
Form: solution for infusion
Active substance Dosage irinotecan hydrochloride trihydrate 1.5 mg/ml ATC: L01CE02
Manufacturer: Sun Pharmaceutical Industries Europe B.V., Terapia S.A.